Intranuclear inclusions of polyQ-expanded ATXN1 sequester RNA molecules

Front Mol Neurosci. 2023 Dec 6:16:1280546. doi: 10.3389/fnmol.2023.1280546. eCollection 2023.

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disease caused by a trinucleotide (CAG) repeat expansion in the ATXN1 gene. It is characterized by the presence of polyglutamine (polyQ) intranuclear inclusion bodies (IIBs) within affected neurons. In order to investigate the impact of polyQ IIBs in SCA1 pathogenesis, we generated a novel protein aggregation model by inducible overexpression of the mutant ATXN1(Q82) isoform in human neuroblastoma SH-SY5Y cells. Moreover, we developed a simple and reproducible protocol for the efficient isolation of insoluble IIBs. Biophysical characterization showed that polyQ IIBs are enriched in RNA molecules which were further identified by next-generation sequencing. Finally, a protein interaction network analysis indicated that sequestration of essential RNA transcripts within ATXN1(Q82) IIBs may affect the ribosome resulting in error-prone protein synthesis and global proteome instability. These findings provide novel insights into the molecular pathogenesis of SCA1, highlighting the role of polyQ IIBs and their impact on critical cellular processes.

Keywords: RNA sequestration; RNA-seq; ataxin-1; intranuclear inclusion bodies; protein–protein interaction network; ribosome; spinocerebellar ataxia type 1.

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by: (1) the Hellenic Foundation for Research and Innovation (HFRI) and the General Secretariat for Research and Innovation (GSRI) under the 1st Call for research projects to support Postdoctoral Researchers (Grant Agreement No. 122), (2) the HFRI under the 3rd Call for HFRI PhD Fellowships (Fellowship Number: 6654), and (3) the STREAMLINE project funded by Horizon Europe programme Widening Participation and Spreading Excellence (Grant Agreement No. 101060201).